Royalty Report: Drugs, Cancer, Disease – Collection: 275835

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Antibiotic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 275835

License Grant
University grants to Licensees a non-exclusive license under the Subject Patents for Inventor to practice the inventions covered by such Subject Patents at Licensee.
License Property
The patents are titled
4-Demethoxy-3-desamino-2-halo-anthracycline and pharmaceutical composition containing same,
3-Amino-2 halo-anthracycline antibiotics ,
1-fluoro, 4-fluoro, and 1,4-difluoro-2-halo anthracycline antibiotics, and,
1-fluoro, 4-fluoro, and 1,4-difluoro anthracycline anticancer antibiotics.
Field of Use
The field of use is for research purposes only, including sponsored research, with the right to sublicense both research/development activities and commercial manufacture, use and/or sale.

IPSCIO Record ID: 237248

License Grant
The University grants an exclusive license, with the right to sub license, under Universitys  Patent rights to make, have made, import, use, offer to sell and sen any Licensed Products in the field throughout the Territory.

University grants to Licensee the right to enter into sublicensing agreements.

This agreement also includes a non-exclusive grant back to University from Licensee.

License Property
Licensor owns or has rights to certain inventions, generally characterized as Complexes to Improve Oral Absorption of Poorly Absorbable Oral Antibiotics, collectively referred to as the Invention.

First Licensed Product means the first federally approved Individual Licensed Product to be subjected to a governmental safety and efficacy approval process prior to market introduction, and which is sold in any country of the Territory.

Field of Use
Licensee commercializes certain oral formulations of ceftriaxone, a third-generation cephalosporin antibiotic that has activity against both Gram-positive and Gram-negative bacterial infections. Ceftriaxone is currently only marketed in an intravenous, or IV, formulation.

IPSCIO Record ID: 276947

License Grant
Licensor, University foundation, grants Sublicensee a non-exclusive sublicense under the  Patents for Inventor to practice the inventions covered by such Subject Patents at Sublicensee to the University.
License Property
Licensor is the exclusive licensee, under license agreements between the University and the United States Department of Health and Human Services to certain Subject Patents.  The patents ate titled 7-O-(2,6-Dideoxy-.alpha.-L-lyxo-hexopyranosyl)-daunomycinone, desmethoxy daunomycinone, adriamycinone, and carminomycinone , and, 2Halo derivatives of daunomycin, desmethoxy daunomycin, adriamycin and carminomycin.
Field of Use
The field of use is for research purposes only, including sponsored research, with the right to sublicense both research/development activities and commercial manufacture, use and/or sale.  These inventions relate to compounds showing high antileukemic activity.

Antileukemic drugs are anticancer drugs that are used to treat one or more types of leukemia.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.